
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
K190222
B. Purpose for Submission:
To obtain a substantial equivalence determination for the FilmArray
Pneumonia/Pneumoniaplus Control, P/N M340
C. Measurand:
Multi-analyte quality control materials
D. Type of Test:
FilmArray Pneumonia/Pneumoniaplus Control is intended for in vitro diagnostic use as
external assayed quality control materials to monitor the qualitative amplification, detection
and identification steps of the laboratory nucleic acid test, FilmArray Pneumonia
Panel/Pneumonia plus Panel on the FilmArray systems, which detects respiratory pathogens:
Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae complex,
Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Klebsiella oxytoca,
Klebsiella pneumoniae group, Moraxella catarrhalis, Proteus spp., Pseudomonas
aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae,
Streptococcus pneumoniae, Streptococcus pyogenes, Chlamydia pneumoniae, Legionella
pneumophila, Mycoplasma pneumoniae; antimicrobial resistance genes: CTX-M, IMP, KPC,
mecA/C and MREJ, NDM, OXA-48 like, VIM; and viruses: Adenovirus, Coronavirus,
Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza B, Middle
East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza Virus and Respiratory
Syncytial Virus.
E. Applicant:
Maine Molecular Quality Controls, Inc. (MMQCI)
F. Proprietary and Established Names:
FilmArray Pneumonia/Pneumoniaplus Control, P/N M340
FilmArray Pneumonia/Pneumoniaplus Control
G. Regulatory Information:
1. Regulation section:

--- Page 2 ---
21 CFR 866.3920, Assayed quality control material for clinical microbiology assays
2. Classification:
Class II (Special Controls)
3. Product code:
PMN
4. Panel:
83- Microbiology
H. Indication(s) for use:
1. Indications for use(s):
FilmArray Pneumonia/Pneumoniaplus Control is intended for use as an external positive
and negative assayed quality control to monitor performance of in vitro laboratory
nucleic acid testing procedures for the qualitative detection of bacteria: Acinetobacter
calcoaceticus-baumannii complex, Enterobacter cloacae complex, Escherichia coli,
Haemophilus influenzae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella
pneumoniae group, Moraxella catarrhalis, Proteus spp., Pseudomonas aeruginosa,
Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus
pneumoniae, Streptococcus pyogenes, Chlamydia pneumoniae, Legionella pneumophila,
Mycoplasma pneumoniae; antimicrobial resistance genes: CTX-M, IMP, KPC, mecA/C
and MREJ, NDM, OXA-48 like, VIM; and viruses: Adenovirus, Coronavirus, Human
Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza B, Middle
East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza Virus and
Respiratory Syncytial Virus on the FilmArray Pneumonia Panel or Pneumonia Panel plus
assays performed on FilmArray systems. FilmArray Pneumonia/Pneumoniaplus Control
is composed of synthetic DNA and RNA specifically designed for and intended to be
used solely with the FilmArray Pneumonia Panel and FilmArray Pneumonia Panel plus
assays. This product is not intended to replace manufacturer controls provided with the
device.
2. Special conditions for use statement(s):
For in vitro diagnostic use only
For prescription use only
3. Special instrument requirements:
FilmArray Pneumonia/Pneumoniaplus Control Panel was evaluated on the FilmArray 2.0
instrument.

--- Page 3 ---
I. Device Description:
FilmArray Pneumonia/Pneumoniaplus Control, P/N M340, is a quality control panel
consisting of 2 controls, FilmArray Pneumonia/Pneumoniaplus Positive (Positive Control),
P/N M34235, and FilmArray Pneumonia/Pneumoniaplus Negative, (Negative Control), P/N
M34135. The Positive Control contains non-infectious surrogate control material; a solution
of synthetic DNA and RNA in buffers, stabilizers and preservatives. The DNA and RNA in
the Positive Control carries nucleic acid corresponding to the genome segments of all the
respiratory pathogens and antimicrobial resistance genes detected and identified by the
FilmArray Pneumonia Panel and Pneumonia Panel plus assays (see Table 1 below) on the
FilmArray systems. The Negative Control contains only buffers, stabilizers and
preservatives. Each liquid control of FilmArray Pneumonia/Pneumoniaplus Control is
processed separately according to FilmArray Pneumonia Panel or Pneumonia Panel plus
assays manufacturer’s Instructions for Use for patient samples (Sputum) obtained from
individuals suspected of lower respiratory tract infection. Each tube of control contains
sufficient liquid for a single use.
The FilmArray Pneumonia/Pneumoniaplus Positive Control is prepared nucleic acid
concentrations of 5X-10X LoD for each of the organisms detected by the FilmArray
Pneumonia/Pneumonia plus assay.
Table 1. Respiratory pathogens and antimicrobial resistance genes detected by
FilmArray Pneumonia Panel & Pneumonia Panel plus assays.
Bacteria
Acinetobacter calcoaceticus-baumannii
Pseudomonas aeruginosa
complex
Enterobacter cloacae complex Serratia marcescens
Escherichia coli Staphylococcus aureus
Haemophilus influenzae Streptococcus agalactiae
Klebsiella aerogenes Streptococcus pneumoniae
Klebsiella oxytoca Streptococcus pyogenes
Klebsiella pneumoniae group Chlamydia pneumoniae
Moraxella catarrhalis Legionella pneumophila
Proteus spp. Mycoplasma pneumoniae
Antimicrobial Resistance Genes
CTX-M NDM
IMP OXA-48 like
KPC VIM
mecA/C and MREJ
Viruses
Adenovirus Influenza B

[Table 1 on page 3]
	Bacteria	
Acinetobacter calcoaceticus-baumannii
complex		Pseudomonas aeruginosa
Enterobacter cloacae complex		Serratia marcescens
Escherichia coli		Staphylococcus aureus
Haemophilus influenzae		Streptococcus agalactiae
Klebsiella aerogenes		Streptococcus pneumoniae
Klebsiella oxytoca		Streptococcus pyogenes
Klebsiella pneumoniae group		Chlamydia pneumoniae
Moraxella catarrhalis		Legionella pneumophila
Proteus spp.		Mycoplasma pneumoniae
	Antimicrobial Resistance Genes	
CTX-M		NDM
IMP		OXA-48 like
KPC		VIM
mecA/C and MREJ		
	Viruses	
Adenovirus		Influenza B

--- Page 4 ---
Middle East Respiratory Syndrome
Coronavirus
Coronavirus*
Human Metapneumovirus Parainfluenza Virus
Human Rhinovirus/Enterovirus Respiratory Syncytial Virus
Influenza A
*Detected by FilmArray Pneumonia Panel plus assay only.
J. Substantial Equivalence Information:
1. Predicate device name(s):
FilmArray RP EZ Control Panel M265, Maine Molecular Quality Controls, Inc.
2. Predicate 510(k) number(s):
K161573
3. Comparison with predicate:
Similarities
Device: FilmArray Predicate: FilmArray RP EZ
Item Pneumonia/Pneumoniaplus Control Panel M265
Control (K173171) (K161573)
FilmArray Pneumonia/Pneumoniaplus FilmArray RP EZ Control Panel M265 is
Control is intended for use as an external intended for use as external positive and
positive and negative assayed quality negative, surrogate assayed quality
control to monitor performance of in vitro control materials to monitor the
performance of in vitro laboratory nucleic
laboratory nucleic acid testing procedures
acid testing procedures for the qualitative
for the qualitative detection of bacteria:
detection of Adenovirus, Coronavirus,
Acinetobacter calcoaceticus-baumannii
Human Metapneumovirus, Human
complex, Enterobacter cloacae complex,
Rhinovirus/ Enterovirus, Influenza A,
Escherichia coli, Haemophilus influenzae,
Influenza A subtype H1, Influenza A
Klebsiella aerogenes, Klebsiella oxytoca,
subtype H3, Influenza A subtype H1-
Klebsiella pneumoniae group, Moraxella
2009, Influenza B, Parainfluenza Virus,
catarrhalis, Proteus spp., Pseudomonas
Intended Use Respiratory Syncytial Virus, Bordetella
aeruginosa, Serratia marcescens,
pertussis, Chlamydophila pneumoniae,
Staphylococcus aureus, Streptococcus
and Mycoplasma pneumonia on the
agalactiae, Streptococcus pneumoniae, FilmArray RP EZ assay performed on the
Streptococcus pyogenes, Chlamydia FilmArray systems. The control panel
pneumoniae, Legionella pneumophila, also contains a negative control. This
Mycoplasma pneumoniae; antimicrobial product is not intended to replace
resistance genes: CTX-M, IMP, KPC, manufacturer controls provided with the
mecA/C and MREJ, NDM, OXA-48 like, device.
VIM; and viruses: Adenovirus,
Coronavirus, Human Metapneumovirus,
Human Rhinovirus/Enterovirus, Influenza
A, Influenza B, Middle East Respiratory

[Table 1 on page 4]
Coronavirus	Middle East Respiratory Syndrome
Coronavirus*
Human Metapneumovirus	Parainfluenza Virus
Human Rhinovirus/Enterovirus	Respiratory Syncytial Virus
Influenza A	

[Table 2 on page 4]
Similarities		
		
	Device: FilmArray	Predicate: FilmArray RP EZ
Item	Pneumonia/Pneumoniaplus	Control Panel M265
	Control (K173171)	(K161573)
Intended Use	FilmArray Pneumonia/Pneumoniaplus
Control is intended for use as an external
positive and negative assayed quality
control to monitor performance of in vitro
laboratory nucleic acid testing procedures
for the qualitative detection of bacteria:
Acinetobacter calcoaceticus-baumannii
complex, Enterobacter cloacae complex,
Escherichia coli, Haemophilus influenzae,
Klebsiella aerogenes, Klebsiella oxytoca,
Klebsiella pneumoniae group, Moraxella
catarrhalis, Proteus spp., Pseudomonas
aeruginosa, Serratia marcescens,
Staphylococcus aureus, Streptococcus
agalactiae, Streptococcus pneumoniae,
Streptococcus pyogenes, Chlamydia
pneumoniae, Legionella pneumophila,
Mycoplasma pneumoniae; antimicrobial
resistance genes: CTX-M, IMP, KPC,
mecA/C and MREJ, NDM, OXA-48 like,
VIM; and viruses: Adenovirus,
Coronavirus, Human Metapneumovirus,
Human Rhinovirus/Enterovirus, Influenza
A, Influenza B, Middle East Respiratory	FilmArray RP EZ Control Panel M265 is
intended for use as external positive and
negative, surrogate assayed quality
control materials to monitor the
performance of in vitro laboratory nucleic
acid testing procedures for the qualitative
detection of Adenovirus, Coronavirus,
Human Metapneumovirus, Human
Rhinovirus/ Enterovirus, Influenza A,
Influenza A subtype H1, Influenza A
subtype H3, Influenza A subtype H1-
2009, Influenza B, Parainfluenza Virus,
Respiratory Syncytial Virus, Bordetella
pertussis, Chlamydophila pneumoniae,
and Mycoplasma pneumonia on the
FilmArray RP EZ assay performed on the
FilmArray systems. The control panel
also contains a negative control. This
product is not intended to replace
manufacturer controls provided with the
device.

--- Page 5 ---
Similarities
Syndrome Coronavirus (MERS-CoV),
Parainfluenza Virus and Respiratory
Syncytial Virus on the FilmArray
Pneumonia Panel or Pneumonia Panel
plus assays performed on FilmArray
systems. FilmArray
Pneumonia/Pneumoniaplus Control is
composed of synthetic DNA and RNA
specifically designed for and intended to
be used solely with the FilmArray
Pneumonia Panel and FilmArray
Pneumonia Panel plus assays. This
product is not intended to replace
manufacturer controls provided with the
device.
Physical Format Ready-to-Use Liquid Same
Directions for
Process like patient sample Same
Use
Reverse transcription,
Assay Steps
amplification, detection, Same
Monitored
identification
Number of
Multiple Same
Targets
Differences
Device: FilmArray Predicate: FilmArray RP EZ
Item Pneumonia/Pneumoniaplus Control Panel M265
Control (K173171) (K161573)
Acinetobacter calcoaceticus-baumannii Adenovirus, Coronavirus, Human
complex, Enterobacter cloacae complex, Metapneumovirus, Human Rhinovirus/
Escherichia coli, Haemophilus influenzae, Enterovirus, Influenza A, Influenza A
Klebsiella aerogenes, Klebsiella oxytoca, subtype H1, Influenza A subtype H3,
Influenza A subtype H1-2009, Influenza
Klebsiella pneumoniae group, Moraxella
B, Parainfluenza Virus, Respiratory
catarrhalis, Proteus spp., Pseudomonas
Syncytial Virus, Bordetella pertussis,
aeruginosa, Serratia marcescens,
Chlamydophila pneumoniae, and
Staphylococcus aureus, Streptococcus
Mycoplasma pneumonia
agalactiae, Streptococcus pneumoniae,
Targets
Streptococcus pyogenes, Chlamydia
pneumoniae, Legionella pneumophila,
Mycoplasma pneumoniae; antimicrobial
resistance genes: CTX-M, IMP, KPC,
mecA/C and MREJ, NDM, OXA-48 like,
VIM; and viruses: Adenovirus,
Coronavirus, Human Metapneumovirus,
Human Rhinovirus/Enterovirus, Influenza
A, Influenza B, Middle East Respiratory

[Table 1 on page 5]
Similarities		
		
	Syndrome Coronavirus (MERS-CoV),
Parainfluenza Virus and Respiratory
Syncytial Virus on the FilmArray
Pneumonia Panel or Pneumonia Panel
plus assays performed on FilmArray
systems. FilmArray
Pneumonia/Pneumoniaplus Control is
composed of synthetic DNA and RNA
specifically designed for and intended to
be used solely with the FilmArray
Pneumonia Panel and FilmArray
Pneumonia Panel plus assays. This
product is not intended to replace
manufacturer controls provided with the
device.	
Physical Format	Ready-to-Use Liquid	Same
Directions for
Use	Process like patient sample	Same
Assay Steps
Monitored	Reverse transcription,
amplification, detection,
identification	Same
Number of
Targets	Multiple	Same

[Table 2 on page 5]
Differences		
		
	Device: FilmArray	Predicate: FilmArray RP EZ
Item	Pneumonia/Pneumoniaplus	Control Panel M265
	Control (K173171)	(K161573)
Targets	Acinetobacter calcoaceticus-baumannii
complex, Enterobacter cloacae complex,
Escherichia coli, Haemophilus influenzae,
Klebsiella aerogenes, Klebsiella oxytoca,
Klebsiella pneumoniae group, Moraxella
catarrhalis, Proteus spp., Pseudomonas
aeruginosa, Serratia marcescens,
Staphylococcus aureus, Streptococcus
agalactiae, Streptococcus pneumoniae,
Streptococcus pyogenes, Chlamydia
pneumoniae, Legionella pneumophila,
Mycoplasma pneumoniae; antimicrobial
resistance genes: CTX-M, IMP, KPC,
mecA/C and MREJ, NDM, OXA-48 like,
VIM; and viruses: Adenovirus,
Coronavirus, Human Metapneumovirus,
Human Rhinovirus/Enterovirus, Influenza
A, Influenza B, Middle East Respiratory	Adenovirus, Coronavirus, Human
Metapneumovirus, Human Rhinovirus/
Enterovirus, Influenza A, Influenza A
subtype H1, Influenza A subtype H3,
Influenza A subtype H1-2009, Influenza
B, Parainfluenza Virus, Respiratory
Syncytial Virus, Bordetella pertussis,
Chlamydophila pneumoniae, and
Mycoplasma pneumonia

--- Page 6 ---
Differences
Syndrome Coronavirus (MERS-CoV),
Parainfluenza Virus and Respiratory
Syncytial Virus
Composition Synthetic RNA & DNA transcripts Synthetic RNA transcripts
K. Standard/Guidance Document Referenced (if applicable):
None were referenced
L. Test Principle:
Not applicable
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Reproducibility:
A multi-site reproducibility study was performed with the FilmArray
Pneumonia/Pneumoniaplus Control on FilmArray instrument 2.0 and FilmArray
Torch systems. Testing consisted of three positive and three negative controls run per
day and spanned a period of 10 days. Multiple operators participated in testing at each
of the three locations. Three lots each of external control material and three lots of
FilmArray Pneumonia/Pneumoniaplus pouch lots were tested across all sites. A total
of 185 external controls were tested (93 positive and 92 negative). The results are
shown in the Tables 2 below:

[Table 1 on page 6]
Differences		
		
	Syndrome Coronavirus (MERS-CoV),
Parainfluenza Virus and Respiratory
Syncytial Virus	
Composition	Synthetic RNA & DNA transcripts	Synthetic RNA transcripts

--- Page 7 ---
Table 2: FilmArray Pneumonia/Pneumoniaplus Control Reproducibility Study Summary
All Sites All Sites
SITE
Site #1 Site #2 Site #3
Category % % %
#expected Agreement #expected Agreement #expected Agreement Overall 95%
results/# with results/# with results/# with Percent Confidence
tested1 Expected tested Expected tested Expected Agreement Interval
Result 1 Result 1 Result 1
FilmArray
96.8% 90.9% to
Positive 30/30 100% 30/32 93.8% 30/31 96.8%
90/93 98.9%
Control
FilmArray
97.8% 92.4% to
Negative 30/31 96.8% 30/31 96.8% 30/30 100%
90/92 99.4%
Control
1 Expected result for the FilmArray Pneumonia/Pneumoniaplus Positive Control is positive. Expected result for the FilmArray
Pneumonia/Pneumoniaplus Negative Control is negative
Table 3: Reproducibility External Crossing Point (Cp) Summary
Site 1 Site 2 Site 3 All External Sites
Analyte
Ave Cp SD Ave Cp SD Ave Cp SD Ave Cp SD %CV
Acinetobacter 15.3 0.6 16.0 0.8 16.0 1.0 15.6 0.9 5.6%
Adenovirus 2 11.6 0.9 12.2 0.9 12.3 1.5 11.9 1.2 9.8%
Adenovirus 3 10.7 0.8 11.3 0.8 11.4 1.4 11.0 1.0 9.4%
Adenovirus 7 11.8 0.7 12.1 1.1 11.9 1.0 11.8 1.0 8.1%
C. pneumoniae 12.4 0.6 12.2 0.6 12.6 0.7 12.3 0.6 5.3%
Coronavirus 16.7 1.1 16.6 0.8 17.1 0.9 16.6 0.9 5.6%
CTX-M 12.9 0.9 13.6 0.8 13.7 1.4 13.3 1.1 8.4%
E. coli 12.3 0.6 12.7 0.9 12.8 1.2 12.6 0.9 7.5%
Enterobacter 1 13.4 0.8 14.0 1.0 14.1 1.4 13.7 1.1 8.2%
Enterobacter 2 13.0 0.8 13.6 1.0 13.6 1.2 13.3 1.0 7.8%
H. influenzae 13.8 0.9 14.2 1.3 14.1 1.2 13.9 1.2 8.7%
K. oxytoca 13.0 0.7 13.7 1.0 13.8 1.4 13.4 1.1 8.1%
K. pneumoniae 15.2 0.8 15.8 0.9 15.9 1.3 15.5 1.0 6.7%
M. catarrhalis 13.1 0.7 13.6 1.0 13.5 1.1 13.3 1.0 7.3%
P. aeruginosa 14.8 0.8 15.5 0.9 15.6 1.5 15.1 1.2 7.7%
Proteus 14.2 0.7 14.8 0.9 14.8 0.9 14.4 0.9 6.2%
S. marcescens 15.0 0.6 15.4 0.9 15.4 1.0 15.1 0.9 5.8%
hMPV 16.0 0.8 15.7 0.8 16.3 1.1 15.8 0.9 5.9%
HRV/EV 14.2 0.7 14.0 0.8 14.6 0.9 14.1 0.8 5.7%
IMP 10.7 0.7 11.1 1.0 11.0 1.0 10.8 0.9 8.5%
Flu A 15.4 1.4 15.3 1.3 15.9 1.3 15.4 1.3 8.7%
Flu B 14.2 0.7 14.0 0.7 14.5 0.7 14.1 0.7 5.0%
KPC 16.6 0.8 16.6 0.8 17.3 1.2 16.7 1.0 5.9%

[Table 1 on page 7]
Category	SITE													All Sites			All Sites	
													Overall
Percent
Agreement			95%
Confidence
Interval		
		Site #1				Site #2				Site #3								
	#expected
results/#
tested1		%
Agreement
with
Expected
Result 1		#expected
results/#
tested		%
Agreement
with
Expected
Result 1		#expected
results/#
tested		%
Agreement
with
Expected
Result 1							
FilmArray
Positive
Control	30/30		100%		30/32		93.8%		30/31		96.8%		96.8%
90/93			90.9% to
98.9%		
FilmArray
Negative
Control	30/31		96.8%		30/31		96.8%		30/30		100%		97.8%
90/92			92.4% to
99.4%		

[Table 2 on page 7]
Analyte	Site 1		Site 2		Site 3		All External Sites		
	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	%CV
									
Acinetobacter	15.3	0.6	16.0	0.8	16.0	1.0	15.6	0.9	5.6%
Adenovirus 2	11.6	0.9	12.2	0.9	12.3	1.5	11.9	1.2	9.8%
Adenovirus 3	10.7	0.8	11.3	0.8	11.4	1.4	11.0	1.0	9.4%
Adenovirus 7	11.8	0.7	12.1	1.1	11.9	1.0	11.8	1.0	8.1%
C. pneumoniae	12.4	0.6	12.2	0.6	12.6	0.7	12.3	0.6	5.3%
Coronavirus	16.7	1.1	16.6	0.8	17.1	0.9	16.6	0.9	5.6%
CTX-M	12.9	0.9	13.6	0.8	13.7	1.4	13.3	1.1	8.4%
E. coli	12.3	0.6	12.7	0.9	12.8	1.2	12.6	0.9	7.5%
Enterobacter 1	13.4	0.8	14.0	1.0	14.1	1.4	13.7	1.1	8.2%
Enterobacter 2	13.0	0.8	13.6	1.0	13.6	1.2	13.3	1.0	7.8%
H. influenzae	13.8	0.9	14.2	1.3	14.1	1.2	13.9	1.2	8.7%
K. oxytoca	13.0	0.7	13.7	1.0	13.8	1.4	13.4	1.1	8.1%
K. pneumoniae	15.2	0.8	15.8	0.9	15.9	1.3	15.5	1.0	6.7%
M. catarrhalis	13.1	0.7	13.6	1.0	13.5	1.1	13.3	1.0	7.3%
P. aeruginosa	14.8	0.8	15.5	0.9	15.6	1.5	15.1	1.2	7.7%
Proteus	14.2	0.7	14.8	0.9	14.8	0.9	14.4	0.9	6.2%
S. marcescens	15.0	0.6	15.4	0.9	15.4	1.0	15.1	0.9	5.8%
hMPV	16.0	0.8	15.7	0.8	16.3	1.1	15.8	0.9	5.9%
HRV/EV	14.2	0.7	14.0	0.8	14.6	0.9	14.1	0.8	5.7%
IMP	10.7	0.7	11.1	1.0	11.0	1.0	10.8	0.9	8.5%
Flu A	15.4	1.4	15.3	1.3	15.9	1.3	15.4	1.3	8.7%
Flu B	14.2	0.7	14.0	0.7	14.5	0.7	14.1	0.7	5.0%
KPC	16.6	0.8	16.6	0.8	17.3	1.2	16.7	1.0	5.9%

--- Page 8 ---
Site 1 Site 2 Site 3 All External Sites
Analyte
Ave Cp SD Ave Cp SD Ave Cp SD Ave Cp SD %CV
L. pneumophila 13.8 0.8 13.7 0.7 14.4 0.9 13.8 0.8 6.0%
mecA/C 14.5 0.9 15.1 1.2 15.0 1.1 14.7 1.1 7.5%
MREJ 14.2 0.8 14.7 1.3 14.5 1.2 14.3 1.1 7.8%
S. aureus1 13.5 0.7 14.0 1.0 13.8 1.1 13.6 1.0 7.1%
S. aureus 2 14.3 0.7 14.8 1.0 14.7 1.0 14.5 0.9 6.5%
MERS 1 15.7 1.1 15.6 0.8 16.3 1.1 15.7 1.0 6.7%
MERS 2 14.5 1.3 14.4 1.0 15.0 1.2 14.5 1.2 8.1%
M. pneumoniae 13.6 0.6 13.4 0.6 13.8 0.8 13.5 0.7 4.9%
NDM 12.3 1.0 13.1 1.0 13.3 1.3 12.8 1.1 8.9%
OXAa 13.8 0.7 13.5 0.7 14.1 0.8 13.6 0.7 5.4%
PIV 13.7 0.6 13.5 0.7 14.0 0.6 13.6 0.7 4.9%
S. agalactiae 12.6 0.7 13.1 1.0 13.0 1.0 12.8 0.9 7.3%
S. pneumoniae 12.6 0.7 13.0 0.9 13.0 0.9 12.7 0.9 6.9%
S. pyogenes 13.0 0.6 13.3 0.9 13.3 0.9 13.0 0.9 6.6%
VIM 13.0 0.7 13.6 0.9 13.6 1.2 13.3 1.0 7.3%
RSV 12.0 0.5 11.8 0.6 12.2 0.7 11.9 0.6 5.3%
The results suggest that there are no significant differences between different users
and different sites on different days. External reproducibility studies for the
FilmArray Pneumonia/Pneumoniaplus Control are acceptable.
b. Precision:
An internal precision study for the FilmArray Pneumonia/Pneumoniaplus Control was
conducted over sixty days by testing three FilmArray Pneumonia/Pneumoniaplus
Control Panel lots with three FilmArray Pneumonia/Pneumoniaplus assay lots
performed by three operators using two FilmArray 2.0 instruments. All Positive
Controls gave correct results except for 3 which gave false negative results. Repeat
tests gave correct results on the first retest. All Negative Controls gave correct results.
The results are shown in the Table 4 below:

[Table 1 on page 8]
Analyte	Site 1		Site 2		Site 3		All External Sites		
	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	%CV
									
L. pneumophila	13.8	0.8	13.7	0.7	14.4	0.9	13.8	0.8	6.0%
mecA/C	14.5	0.9	15.1	1.2	15.0	1.1	14.7	1.1	7.5%
MREJ	14.2	0.8	14.7	1.3	14.5	1.2	14.3	1.1	7.8%
S. aureus1	13.5	0.7	14.0	1.0	13.8	1.1	13.6	1.0	7.1%
S. aureus 2	14.3	0.7	14.8	1.0	14.7	1.0	14.5	0.9	6.5%
MERS 1	15.7	1.1	15.6	0.8	16.3	1.1	15.7	1.0	6.7%
MERS 2	14.5	1.3	14.4	1.0	15.0	1.2	14.5	1.2	8.1%
M. pneumoniae	13.6	0.6	13.4	0.6	13.8	0.8	13.5	0.7	4.9%
NDM	12.3	1.0	13.1	1.0	13.3	1.3	12.8	1.1	8.9%
OXAa	13.8	0.7	13.5	0.7	14.1	0.8	13.6	0.7	5.4%
PIV	13.7	0.6	13.5	0.7	14.0	0.6	13.6	0.7	4.9%
S. agalactiae	12.6	0.7	13.1	1.0	13.0	1.0	12.8	0.9	7.3%
S. pneumoniae	12.6	0.7	13.0	0.9	13.0	0.9	12.7	0.9	6.9%
S. pyogenes	13.0	0.6	13.3	0.9	13.3	0.9	13.0	0.9	6.6%
VIM	13.0	0.7	13.6	0.9	13.6	1.2	13.3	1.0	7.3%
RSV	12.0	0.5	11.8	0.6	12.2	0.7	11.9	0.6	5.3%

--- Page 9 ---
Table 4: FilmArray Pneumonia/Pneumoniaplus Control Precision Summary
#expected results/ Overall Percent 95% Confidence
Category
#tested1 Agreement Interval
FilmArray
Pneumonia/Pneumoniaplus 60/60 100% 94% to 100%
Negative Control
FilmArray
Pneumonia/Pneumoniaplus 60/63* 95% 86.9% to 98.4%
Positive Control
1Expected result for the FilmArray Pneumonia/Pneumoniaplus Positive Control is positive. Expected result for the FilmArray
Pneumonia/Pneumoniaplus Negative Control is negative.
* Three Positive controls gave initial false negative results, all produced the correct results upon a single retest
Table 5: Precision Internal Crossing Point (Cp) Summary
D04MAY18A A29MAY18A C12JUN18A All Lots
Analyte
Ave Cp SD Ave Cp SD Ave Cp SD Ave Cp SD %CV
Acinetobacter 16.2 1.1 16.2 1.4 15.7 1.2 16.0 1.2 7.6%
Adenovirus 2 13.3 1.9 13.4 2.4 12.5 1.4 13.1 2.0 15.2%
Adenovirus 3 11.9 2.0 11.8 2.2 10.6 0.9 11.4 1.9 16.4%
Adenovirus 7 12.2 1.3 12.2 1.6 11.7 1.4 12.0 1.5 12.2%
C. pneumoniae 12.7 0.6 12.9 0.7 12.8 0.4 12.8 0.6 4.6%
Coronavirus 17.0 0.7 17.3 0.8 17.2 0.7 17.2 0.7 4.3%
CTX-M 14.6 2.0 14.8 2.4 13.9 1.1 14.4 1.9 13.3%
E. coli 13.2 1.7 13.2 1.9 12.3 0.9 12.9 1.6 12.2%
Enterobacter 1 14.5 1.9 14.6 2.2 13.4 1.2 14.2 1.9 13.2%
Enterobacter 2 13.9 1.7 14.0 2.1 13.2 1.2 13.7 1.7 12.6%
H. influenzae 14.3 1.5 14.2 1.8 13.9 1.4 14.1 1.6 11.3%
K. oxytoca 14.1 2.0 14.2 2.4 12.9 1.1 13.7 2.0 14.6%
K. pneumoniae 16.1 1.6 16.2 1.9 15.0 0.9 15.7 1.6 10.3%
M. catarrhalis 13.6 1.3 13.6 1.5 12.9 1.2 13.4 1.4 10.3%
P. aeruginosa 16.2 2.2 16.2 2.5 15.1 0.9 15.8 2.0 12.7%
Proteus 15.2 1.1 15.2 1.3 14.6 0.8 15.0 1.1 7.3%
S. marcescens 15.6 1.2 15.5 1.5 14.8 1.0 15.3 1.3 8.4%
hMPV 17.2 0.9 17.5 1.1 17.6 2.1 17.4 1.5 8.4%
HRV/EV 14.8 1.3 15.1 1.4 14.6 0.5 14.8 1.2 7.9%
IMP 11.5 1.3 11.4 1.6 11.1 1.5 11.4 1.5 12.8%
Flu A 16.4 1.5 16.7 1.6 16.0 0.8 16.4 1.4 8.3%
Flu B 14.7 0.7 15.0 0.7 14.7 0.4 14.8 0.6 4.2%
KPC 17.5 1.3 17.8 1.5 16.9 0.8 17.4 1.3 7.4%
L. pneumophila 14.4 1.0 14.7 1.0 14.2 0.5 14.4 0.9 6.1%
mecA/C 15.2 1.2 15.1 1.5 14.8 1.2 15.0 1.3 8.5%
MREJ 14.8 1.2 14.6 1.5 14.7 1.8 14.7 1.5 10.3%
S. aureus 1 14.0 1.1 14.0 1.4 13.7 1.1 13.9 1.2 8.5%

[Table 1 on page 9]
Category		#expected results/			Overall Percent			95% Confidence	
		#tested1			Agreement			Interval	
FilmArray
Pneumonia/Pneumoniaplus
Negative Control	60/60			100%			94% to 100%		
FilmArray
Pneumonia/Pneumoniaplus
Positive Control	60/63*			95%			86.9% to 98.4%		

[Table 2 on page 9]
Analyte									
	D04MAY18A		A29MAY18A		C12JUN18A		All Lots		
									
	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	%CV
Acinetobacter	16.2	1.1	16.2	1.4	15.7	1.2	16.0	1.2	7.6%
Adenovirus 2	13.3	1.9	13.4	2.4	12.5	1.4	13.1	2.0	15.2%
Adenovirus 3	11.9	2.0	11.8	2.2	10.6	0.9	11.4	1.9	16.4%
Adenovirus 7	12.2	1.3	12.2	1.6	11.7	1.4	12.0	1.5	12.2%
C. pneumoniae	12.7	0.6	12.9	0.7	12.8	0.4	12.8	0.6	4.6%
Coronavirus	17.0	0.7	17.3	0.8	17.2	0.7	17.2	0.7	4.3%
CTX-M	14.6	2.0	14.8	2.4	13.9	1.1	14.4	1.9	13.3%
E. coli	13.2	1.7	13.2	1.9	12.3	0.9	12.9	1.6	12.2%
Enterobacter 1	14.5	1.9	14.6	2.2	13.4	1.2	14.2	1.9	13.2%
Enterobacter 2	13.9	1.7	14.0	2.1	13.2	1.2	13.7	1.7	12.6%
H. influenzae	14.3	1.5	14.2	1.8	13.9	1.4	14.1	1.6	11.3%
K. oxytoca	14.1	2.0	14.2	2.4	12.9	1.1	13.7	2.0	14.6%
K. pneumoniae	16.1	1.6	16.2	1.9	15.0	0.9	15.7	1.6	10.3%
M. catarrhalis	13.6	1.3	13.6	1.5	12.9	1.2	13.4	1.4	10.3%
P. aeruginosa	16.2	2.2	16.2	2.5	15.1	0.9	15.8	2.0	12.7%
Proteus	15.2	1.1	15.2	1.3	14.6	0.8	15.0	1.1	7.3%
S. marcescens	15.6	1.2	15.5	1.5	14.8	1.0	15.3	1.3	8.4%
hMPV	17.2	0.9	17.5	1.1	17.6	2.1	17.4	1.5	8.4%
HRV/EV	14.8	1.3	15.1	1.4	14.6	0.5	14.8	1.2	7.9%
IMP	11.5	1.3	11.4	1.6	11.1	1.5	11.4	1.5	12.8%
Flu A	16.4	1.5	16.7	1.6	16.0	0.8	16.4	1.4	8.3%
Flu B	14.7	0.7	15.0	0.7	14.7	0.4	14.8	0.6	4.2%
KPC	17.5	1.3	17.8	1.5	16.9	0.8	17.4	1.3	7.4%
L. pneumophila	14.4	1.0	14.7	1.0	14.2	0.5	14.4	0.9	6.1%
mecA/C	15.2	1.2	15.1	1.5	14.8	1.2	15.0	1.3	8.5%
MREJ	14.8	1.2	14.6	1.5	14.7	1.8	14.7	1.5	10.3%
S. aureus 1	14.0	1.1	14.0	1.4	13.7	1.1	13.9	1.2	8.5%

--- Page 10 ---
D04MAY18A A29MAY18A C12JUN18A All Lots
Analyte
S. aureus 2 15.0 1.1 14.9 1.3 14.5 1.0 14.8 1.2 7.8%
MERS1 16.6 1.2 16.9 0.9 16.5 0.5 16.7 0.9 5.6%
MERS2 15.3 1.3 15.6 1.2 15.2 0.8 15.4 1.1 7.1%
M. pneumoniae 14.0 0.6 14.2 0.7 14.2 0.6 14.1 0.6 4.4%
NDM 13.2 1.8 13.2 2.2 12.0 1.0 12.8 1.8 14.1%
OXAa 14.2 0.9 14.5 0.9 14.0 0.6 14.3 0.8 5.8%
PIV 13.9 0.6 14.2 0.7 14.0 0.8 14.0 0.7 4.9%
S. agalactiae 13.1 1.2 13.1 1.3 12.9 1.1 13.0 1.2 9.0%
S. pneumoniae 13.2 1.3 13.2 1.5 12.5 1.0 13.0 1.3 9.8%
S. pyogenes 13.6 1.0 13.6 1.3 13.3 0.9 13.5 1.1 7.9%
VIM 13.9 1.4 13.8 1.7 13.0 0.9 13.5 1.4 10.2%
RSV 12.0 0.6 12.3 0.6 12.1 0.7 12.1 0.6 5.2%
There appears to be no significant differences in mean Cp value when testing different
control lots on different days. Precision studies are acceptable.
c. Within-run Testing:
Within-run precision was demonstrated in a separate study conducted by one operator
testing one lot of FilmArray Pneumonia/Pneumoniaplus Control with one lot of
FilmArray Pneumonia/Pneumonia plus pouches on the FilmArray 2.0, each within one
day. The results are shown in the tables below:
Table 6: FilmArray Pneumonia/Pneumoniaplus Control Panel Summary of Within-run
Precision
#expected results/ Overall Percent 95% Confidence
Control
#tested1 Agreement Interval
FilmArray Pneumonia / Pneumoniaplus
6/6 100% 61%-100%
Positive Control
FilmArray Pneumonia / Pneumoniaplus
6/6 100% 61%-100%
Negative Control
1Expected result for the FilmArray Pneumonia/Pneumoniaplus Positive Control is positive. Expected result for the FilmArray
Pneumonia/Pneumoniaplus Negative Control is negative.

[Table 1 on page 10]
Analyte									
	D04MAY18A		A29MAY18A		C12JUN18A		All Lots		
									
S. aureus 2	15.0	1.1	14.9	1.3	14.5	1.0	14.8	1.2	7.8%
MERS1	16.6	1.2	16.9	0.9	16.5	0.5	16.7	0.9	5.6%
MERS2	15.3	1.3	15.6	1.2	15.2	0.8	15.4	1.1	7.1%
M. pneumoniae	14.0	0.6	14.2	0.7	14.2	0.6	14.1	0.6	4.4%
NDM	13.2	1.8	13.2	2.2	12.0	1.0	12.8	1.8	14.1%
OXAa	14.2	0.9	14.5	0.9	14.0	0.6	14.3	0.8	5.8%
PIV	13.9	0.6	14.2	0.7	14.0	0.8	14.0	0.7	4.9%
S. agalactiae	13.1	1.2	13.1	1.3	12.9	1.1	13.0	1.2	9.0%
S. pneumoniae	13.2	1.3	13.2	1.5	12.5	1.0	13.0	1.3	9.8%
S. pyogenes	13.6	1.0	13.6	1.3	13.3	0.9	13.5	1.1	7.9%
VIM	13.9	1.4	13.8	1.7	13.0	0.9	13.5	1.4	10.2%
RSV	12.0	0.6	12.3	0.6	12.1	0.7	12.1	0.6	5.2%

[Table 2 on page 10]
	#expected results/	Overall Percent	95% Confidence
Control			
	#tested1	Agreement	Interval
			
FilmArray Pneumonia / Pneumoniaplus
Positive Control	6/6	100%	61%-100%
FilmArray Pneumonia / Pneumoniaplus
Negative Control	6/6	100%	61%-100%

--- Page 11 ---
Table 7: Within-run Precision Internal Crossing Point (Cp) Summary
Analyte Mean Cp Standard Deviation
Acinetobacter 15.7 0.8
Adenovirus 2 12.8 1.9
Adenovirus 3 11.5 1.5
Adenovirus 7 11.4 0.5
C. pneumoniae 12.9 0.2
Coronavirus 17.8 0.5
CTX-M 14.1 1.6
E. coli 12.5 1.1
Enterobacter 1 13.7 1.2
Enterobacter 2 13.1 1.0
H. influenzae 13.0 0.3
K. oxytoca 13.2 1.2
K. pneumoniae 15.9 1.0
M. catarrhalis 13.1 0.5
P. aeruginosa 15.6 1.7
Proteus 14.5 0.6
S. marcescens 15.1 0.6
hMPV 17.0 0.7
HRV/EV 14.6 0.8
IMP 10.7 0.7
Flu A 16.9 0.8
Flu B 15.1 0.3
KPC 17.8 0.6
L. pneumophila 14.7 0.7
mecA/C 14.2 0.4
MREJ 13.7 0.3
S. aureus 1 13.4 0.4
S. aureus 2 14.2 0.4
MERS1 17.1 0.8
MERS2 16.1 0.7
M. pneumoniae 14.1 0.3
NDM 12.9 1.5
OXAa 14.7 0.5
PIV 14.1 0.3
S. agalactiae 12.3 0.3
S. pneumoniae 12.3 0.6
S. pyogenes 12.9 0.4
VIM 13.3 0.6
RSV 12.0 0.1
Within-run reproducibility studies for the FilmArray Pneumonia/Pneumoniaplus
Control are acceptable.

[Table 1 on page 11]
Analyte	Mean Cp	Standard Deviation
Acinetobacter	15.7	0.8
Adenovirus 2	12.8	1.9
Adenovirus 3	11.5	1.5
Adenovirus 7	11.4	0.5
C. pneumoniae	12.9	0.2
Coronavirus	17.8	0.5
CTX-M	14.1	1.6
E. coli	12.5	1.1
Enterobacter 1	13.7	1.2
Enterobacter 2	13.1	1.0
H. influenzae	13.0	0.3
K. oxytoca	13.2	1.2
K. pneumoniae	15.9	1.0
M. catarrhalis	13.1	0.5
P. aeruginosa	15.6	1.7
Proteus	14.5	0.6
S. marcescens	15.1	0.6
hMPV	17.0	0.7
HRV/EV	14.6	0.8
IMP	10.7	0.7
Flu A	16.9	0.8
Flu B	15.1	0.3
KPC	17.8	0.6
L. pneumophila	14.7	0.7
mecA/C	14.2	0.4
MREJ	13.7	0.3
S. aureus 1	13.4	0.4
S. aureus 2	14.2	0.4
MERS1	17.1	0.8
MERS2	16.1	0.7
M. pneumoniae	14.1	0.3
NDM	12.9	1.5
OXAa	14.7	0.5
PIV	14.1	0.3
S. agalactiae	12.3	0.3
S. pneumoniae	12.3	0.6
S. pyogenes	12.9	0.4
VIM	13.3	0.6
RSV	12.0	0.1

--- Page 12 ---
d. Lot-to-Lot Testing:
Lot-to-lot reproducibility was demonstrated by testing three lots of FilmArray
Pneumonia/Pneumoniaplus Positive Control using the same pouch lot. Results are
shown in the following tables.
Table 8: FilmArray Pneumonia/Pneumoniaplus Control Panel Summary of Lot-to-Lot
Reproducibility
Control Lot # Number of Tests Pouch Lot Correct Results
D04MAY18A 7 697017 7/7
A29MAY18A 8 697017 7/8*
C12JUN18A 7 697017 7/7
*1 false negative result for hMPV
Table 9: Lot to Lot Internal Crossing Point (Cp) Summary
D04MAY18A A29MAY18A C12JUN18A All lots All Lots
Analyte
Mean Cp Mean Cp Mean Cp Mean SD
Cp
Acinetobacter 15.5 15.1 15.0 15.2 0.5
Adenovirus 2 12.3 11.8 11.9 12.0 0.9
Adenovirus 3 10.7 10.4 10.2 10.5 0.7
Adenovirus 7 11.2 10.7 10.9 10.9 0.4
C. pneumoniae 12.4 12.6 12.6 12.5 0.4
Coronavirus 17.4 17.7 17.5 17.5 0.4
CTX-M 13.4 13.1 13.4 13.3 0.7
E. coli 11.9 11.7 11.6 11.7 0.5
Enterobacter 1 13.1 12.8 12.9 12.9 0.5
Enterobacter 2 12.5 12.3 12.3 12.4 0.5
H. influenzae 12.8 12.4 12.7 12.7 0.3
K. oxytoca 12.6 12.3 12.2 12.4 0.6
K. pneumoniae 15.4 15.2 14.8 15.1 0.5
M. catarrhalis 12.7 12.4 12.4 12.5 0.4
P. aeruginosa 15.0 14.5 14.7 14.7 0.7
Proteus 14.3 14.0 14.0 14.1 0.4
S. marcescens 15.0 14.3 14.8 14.7 0.4
hMPV 17.0 16.9 17.2 17.1 0.7
HRV/EV 14.0 14.3 14.3 14.2 0.5
IMP 10.5 10.0 10.2 10.2 0.5
Flu A 16.6 16.9 16.1 16.6 0.7
Flu B 14.5 14.8 14.7 14.7 0.4
KPC 17.2 17.3 17.0 17.2 0.5
L. pneumophila 14.2 14.5 14.2 14.3 0.6
mecA/C 14.0 13.7 13.9 13.8 0.3

[Table 1 on page 12]
			
Control Lot #	Number of Tests	Pouch Lot	Correct Results
			
D04MAY18A	7	697017	7/7
A29MAY18A	8	697017	7/8*
C12JUN18A	7	697017	7/7

[Table 2 on page 12]
Analyte	D04MAY18A	A29MAY18A	C12JUN18A	All lots	All Lots
	Mean Cp	Mean Cp	Mean Cp	Mean	SD
					
				Cp	
Acinetobacter	15.5	15.1	15.0	15.2	0.5
Adenovirus 2	12.3	11.8	11.9	12.0	0.9
Adenovirus 3	10.7	10.4	10.2	10.5	0.7
Adenovirus 7	11.2	10.7	10.9	10.9	0.4
C. pneumoniae	12.4	12.6	12.6	12.5	0.4
Coronavirus	17.4	17.7	17.5	17.5	0.4
CTX-M	13.4	13.1	13.4	13.3	0.7
E. coli	11.9	11.7	11.6	11.7	0.5
Enterobacter 1	13.1	12.8	12.9	12.9	0.5
Enterobacter 2	12.5	12.3	12.3	12.4	0.5
H. influenzae	12.8	12.4	12.7	12.7	0.3
K. oxytoca	12.6	12.3	12.2	12.4	0.6
K. pneumoniae	15.4	15.2	14.8	15.1	0.5
M. catarrhalis	12.7	12.4	12.4	12.5	0.4
P. aeruginosa	15.0	14.5	14.7	14.7	0.7
Proteus	14.3	14.0	14.0	14.1	0.4
S. marcescens	15.0	14.3	14.8	14.7	0.4
hMPV	17.0	16.9	17.2	17.1	0.7
HRV/EV	14.0	14.3	14.3	14.2	0.5
IMP	10.5	10.0	10.2	10.2	0.5
Flu A	16.6	16.9	16.1	16.6	0.7
Flu B	14.5	14.8	14.7	14.7	0.4
KPC	17.2	17.3	17.0	17.2	0.5
L. pneumophila	14.2	14.5	14.2	14.3	0.6
mecA/C	14.0	13.7	13.9	13.8	0.3

--- Page 13 ---
D04MAY18A A29MAY18A C12JUN18A All lots All Lots
Analyte
Mean Cp Mean Cp Mean Cp Mean SD
Cp
MREJ 13.6 13.2 13.7 13.5 0.4
S. aureus 1 13.2 12.8 13.2 13.1 0.4
S. aureus 2 14.2 13.7 14.1 14.0 0.4
MERS1 16.7 16.8 16.5 16.7 0.7
MERS2 15.6 15.9 15.4 15.6 0.7
M. pneumoniae 13.7 13.9 14.1 13.9 0.5
NDM 12.0 11.9 11.4 11.8 0.6
OXAa 14.2 14.3 14.3 14.3 0.5
PIV 13.6 13.9 13.9 13.8 0.4
S. agalactiae 12.2 11.9 12.1 12.1 0.3
S. pneumoniae 12.0 11.8 11.8 11.9 0.4
S. pyogenes 12.7 12.4 12.7 12.6 0.4
VIM 12.8 12.5 12.5 12.6 0.3
RSV 11.6 12.0 11.8 11.8 0.4
Lot-to-Lot reproducibility studies for the FilmArray Pneumonia/Pneumoniaplus
Control Panel are acceptable.
e. Linearity/assay reportable range:
Not applicable
f. Traceability, Stability, Expected values (controls, calibrators, or methods):
Traceability:
Not applicable
Stability:
Open Vial Stability: Not applicable because FilmArray Pneumonia/Pneumoniaplus
Control is packaged for single use.
Closed Vial Real-time Stability: An accelerated stability study was performed to
establish the shelf life stability claims for FilmArray Pneumonia/Pneumoniaplus
Control. Based on this study, the FilmArray Pneumonia/Pneumoniaplus Control is
expected to be stable until the expiration date (24 months) when stored frozen (–20°C
or colder) and unopened. This product is for single use.
Real-Time Stability Program: Real-time stability studies are ongoing to support
product claims and to monitor potential assay modifications for which the FilmArray

[Table 1 on page 13]
Analyte	D04MAY18A	A29MAY18A	C12JUN18A	All lots	All Lots
	Mean Cp	Mean Cp	Mean Cp	Mean	SD
					
				Cp	
MREJ	13.6	13.2	13.7	13.5	0.4
S. aureus 1	13.2	12.8	13.2	13.1	0.4
S. aureus 2	14.2	13.7	14.1	14.0	0.4
MERS1	16.7	16.8	16.5	16.7	0.7
MERS2	15.6	15.9	15.4	15.6	0.7
M. pneumoniae	13.7	13.9	14.1	13.9	0.5
NDM	12.0	11.9	11.4	11.8	0.6
OXAa	14.2	14.3	14.3	14.3	0.5
PIV	13.6	13.9	13.9	13.8	0.4
S. agalactiae	12.2	11.9	12.1	12.1	0.3
S. pneumoniae	12.0	11.8	11.8	11.9	0.4
S. pyogenes	12.7	12.4	12.7	12.6	0.4
VIM	12.8	12.5	12.5	12.6	0.3
RSV	11.6	12.0	11.8	11.8	0.4

--- Page 14 ---
Pneumonia/Pneumoniaplus Control is indicated for use. Real-time stability study
protocols and acceptance criteria were reviewed and found to be acceptable.
Shipping Stability: MMQCI ships the FilmArray Pneumonia/Pneumoniaplus Control
on dry ice with overnight delivery, ensuring that the control material remains frozen
upon receipt. The frozen control material is then to be stored at -20oC, as indicated in
the FilmArray Pneumonia/Pneumoniaplus Control package insert. A shipping study
was performed to confirm the shipping process and to investigate the outcome of a
possible shipping delay and subsequent arrival with no dry ice. The study evaluated
two lots of the FilmArray Pneumonia/Pneumoniaplus Positive control that was placed
in dry ice that was stored for two days at ambient temperature of approximately 19-
21°C and then tested using the FilmArray Pneumonia/Pneumonia plus assay. To
simulate a shipping delay, additional samples of the two lots of the Positive Control
that had been stored in dry ice, were removed from the dry ice and placed at ambient
temperature for six days. The ‘delayed’ samples were tested at two and six days of
ambient temperature with the FilmArray Pneumonia/Pneumonia plus assay.
The study demonstrated that the FilmArray Pneumonia/Pneumoniaplus Positive
Control is stable for two days on dry ice in MMQCI’s standard shipping box.
FilmArray Pneumonia/Pneumoniaplus Positive Control is stable after six days at
ambient temperatures of approximately 19-21°C. The FilmArray
Pneumonia/Pneumoniaplus Positive Control should be stored frozen (–20°C or
colder) as indicated in the package insert.
Expected Values:
FilmArray Pneumonia/Pneumoniaplus Control is a qualitative control and the
expected results are listed in the tables below.
Table 10: FilmArray Pneumonia/Pneumoniaplus Positive & Negative Result
Summary
Result Summary
Positive M34235 Negative M34135
Bacteria Bin †
(copies/mL)
Acinetobacter calcoaceticus-
Detected 10^5 Not Detected
baumannii complex
Enterobacter cloacae complex Detected 10^6 Not Detected
Escherichia coli Detected 10^5 Not Detected
Haemophilus influenzae Detected 10^5 Not Detected
Klebsiella aerogenes Detected 10^5 Not Detected
Klebsiella oxytoca Detected 10^5 Not Detected
Klebsiella pneumoniae group Detected 10^5 Not Detected
Moraxella catarrhalis Detected 10^5 Not Detected
Proteus spp. Detected 10^5 Not Detected
Pseudomonas aeruginosa Detected 10^5 Not Detected

[Table 1 on page 14]
Result Summary			
	Positive M34235		Negative M34135
			
Bacteria		Bin †
(copies/mL)	
Acinetobacter calcoaceticus-
baumannii complex	Detected	10^5	Not Detected
Enterobacter cloacae complex	Detected	10^6	Not Detected
Escherichia coli	Detected	10^5	Not Detected
Haemophilus influenzae	Detected	10^5	Not Detected
Klebsiella aerogenes	Detected	10^5	Not Detected
Klebsiella oxytoca	Detected	10^5	Not Detected
Klebsiella pneumoniae group	Detected	10^5	Not Detected
Moraxella catarrhalis	Detected	10^5	Not Detected
Proteus spp.	Detected	10^5	Not Detected
Pseudomonas aeruginosa	Detected	10^5	Not Detected

--- Page 15 ---
Result Summary
Serratia marcescens Detected 10^6 Not Detected
Staphylococcus aureus Detected 10^6 Not Detected
Streptococcus agalactiae Detected 10^6 Not Detected
Streptococcus pneumoniae Detected 10^5 Not Detected
Streptococcus pyogenes Detected 10^6 Not Detected
Antimicrobial Resistance Genes
CTX-M Detected N/A
IMP Detected N/A
KPC Detected N/A
mecA/C and MREJ Detected N/A
NDM Detected N/A
OXA-48-like Detected N/A
VIM Detected N/A
Atypical Bacteria
Chlamydia pneumoniae Detected Not Detected
Legionella pneumophila Detected Not Detected
Mycoplasma pneumoniae Detected Not Detected
Viruses
Adenovirus Detected Not Detected
Coronavirus Detected Not Detected
Human Metapneumovirus Detected Not Detected
Human Rhinovirus/Enterovirus Detected Not Detected
Influenza A Detected Not Detected
Influenza B Detected Not Detected
Middle East Respiratory
Syndrome Coronavirus (MERS- Detected Not Detected
CoV) ‡
Parainfluenza Virus Detected Not Detected
Respiratory Syncytial Virus Detected Not Detected
† Bins (copies/ mL) are approximate and may vary run to run.
‡ Middle East Respiratory Syndrome Coronavirus is reported on FilmArray Pneumonia Panelplus assay only.
Matrix Effects:
A study was performed to evaluate the effect of the FilmArray
Pneumonia/Pneumoniaplus Control Panel in the presence of sputum matrix. A
sputum sample positive for M. catarrhalis was spiked into a negative (by culture)
sputum patient sample and into a negative MMQCI matrix sample and tested in
triplicate by the FilmArray Pneumonia/Pneumonia plus assay. No inhibition and/or
false negative results were observed with either the spiked clinical patient
sample or MMQCI’s negative matrix.
Results demonstrated that samples prepared with FilmArray
Pneumonia/Pneumoniaplus Control sputum matrix showed no inhibition and/or false
negative results were observed with either the spiked clinical patient sample or
MMQCI’s negative matrix.

[Table 1 on page 15]
Result Summary			
Serratia marcescens	Detected	10^6	Not Detected
Staphylococcus aureus	Detected	10^6	Not Detected
Streptococcus agalactiae	Detected	10^6	Not Detected
Streptococcus pneumoniae	Detected	10^5	Not Detected
Streptococcus pyogenes	Detected	10^6	Not Detected
Antimicrobial Resistance Genes			
CTX-M	Detected		N/A
IMP	Detected		N/A
KPC	Detected		N/A
mecA/C and MREJ	Detected		N/A
NDM	Detected		N/A
OXA-48-like	Detected		N/A
VIM	Detected		N/A
Atypical Bacteria			
Chlamydia pneumoniae	Detected		Not Detected
Legionella pneumophila	Detected		Not Detected
Mycoplasma pneumoniae	Detected		Not Detected
Viruses			
Adenovirus	Detected		Not Detected
Coronavirus	Detected		Not Detected
Human Metapneumovirus	Detected		Not Detected
Human Rhinovirus/Enterovirus	Detected		Not Detected
Influenza A	Detected		Not Detected
Influenza B	Detected		Not Detected
Middle East Respiratory
Syndrome Coronavirus (MERS-
CoV) ‡	Detected		Not Detected
Parainfluenza Virus	Detected		Not Detected
Respiratory Syncytial Virus	Detected		Not Detected

--- Page 16 ---
g. Detection limit:
Not applicable
h. Analytical Reactivity (Inclusivity):
Not applicable
i. Cross Reactivity:
Not applicable
j. Interference:
Not applicable
k. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
Not applicable.
3. Clinical Studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not Applicable.
N. Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.

--- Page 17 ---
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.